Key Highlights

  • Ranked by the pre-market gain in the October 28, 2026 snapshot: Aptevo Therapeutics (NASDAQ:APVO) 11.72%, Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) 9.15% and Dyadic International (NASDAQ:DYAI) 7.71%.
  • Ocular Therapeutix (NASDAQ:OCUL) added 6.55% and Alaunos Therapeutics (NASDAQ:TCRT) 6.31%. Top to bottom, the gap is 5.41 points.
  • Aptevo alone has a release close to the session, dated Monday, October 26, 2026. The other four moved without a company announcement dated on or just before it.
  • The five share thin pre-market trading and clinical-stage or early commercial status, but their cash positions vary widely, and that shapes how each gain should be read against the balance sheet.

Aptevo Therapeutics (NASDAQ:APVO): transplant results in leukaemia

Aptevo Therapeutics (NASDAQ:APVO) is a clinical-stage company building multispecific antibodies aimed at blood cancers and solid tumours. Pre-market its stock was at USD 1.43, which implies a prior close near USD 1.28 and erases the decline seen on Tuesday, October 27, 2026. The newest item is the Monday, October 26, 2026 release, issued at 8:05 a.m. ET, reporting that 10 of 47 patients on the mipletamig combination in acute myeloid leukaemia went on to donor stem cell transplant, a possibly curative step. Nothing dated Tuesday, October 27 or Wednesday, October 28, 2026 turned up.

Nine of those transplanted patients were enrolled in the Phase 1b RAINIER trial, and talks with regulators on next steps are planned for the first half of 2027. Cash and equivalents were USD 9.8 million on June 30, 2026, and an August 2026 warrant inducement plus private placement brought in about USD 4.5 million gross. Supporters cite the earlier 93% clinical benefit rate in frontline TP53-mutated disease. Critics point to the small patient count and dilution.

Actinium Pharmaceuticals (NYSEAMERICAN:ATNM): radiotherapy patents and a listing path

Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) is a clinical-stage biopharmaceutical firm developing targeted radiotherapies for cancer. Its pre-market quote of USD 1.55 implies a prior close around USD 1.42. No announcement dated Wednesday, October 28, 2026 or earlier came with the rise. The latest disclosure is a regulatory filing that covers Actimab-A patent grants, an extra manufacturer added to its investigational new drug application and the state of its exchange listing. A thin tape and radiopharmaceutical sentiment seem to be behind the move, an inference.

Two United States patents covering Actimab-A in solid tumours run out in October 2043, and clinical milestones are due between the fourth quarter of 2026 and 2027. The summary for the quarter to June 30, 2026 cites USD 35 million of licence revenue but gives no cash or loss figures. NYSE Regulation accepted a compliance plan on Thursday, June 18, 2026, with a plan period running to Saturday, November 27, 2027, although the company is still out of compliance with Sections 1003(a)(ii) and 1003(a)(iii).

Dyadic International (NASDAQ:DYAI): a protein platform under a going-concern warning

Dyadic International (NASDAQ:DYAI) makes recombinant proteins, which are proteins produced by engineered cells, for biologics, food and nutrition. The pre-market quote was USD 0.4232. No announcement dated Wednesday, October 28, 2026 or earlier was found, so the trigger is unconfirmed. Its latest published results, of Wednesday, August 12, 2026, show second-quarter revenue of USD 961,138 and a net loss of USD 2,123,884, and the move looks like thin trading in a cheap share, an inference.

Cash and investments dropped to USD 4,794,798 at June 30, 2026 from USD 8,587,289 at December 31, 2025. Management flagged substantial doubt about continuing as a going concern, which means doubt that funds will last twelve months. A registered direct offering and private placement raising USD 2.9 million followed on Thursday, August 13, 2026. Early sales of recombinant transferrin and growth factors for cultivated meat are the upside case, while a share price under USD 1.00 brings Nasdaq listing questions.

Ocular Therapeutix (NASDAQ:OCUL): a funded filing plan in wet AMD

Ocular Therapeutix (NASDAQ:OCUL) develops sustained-release retinal treatments and sells the Dextenza ophthalmic insert. It traded at USD 7.16 pre-market. Nothing dated Wednesday, October 28, 2026 came with the move, and the latest notices, of Friday, October 9 and Thursday, October 1, 2026, carried no new data. The advance seems driven by thin trading or sector flows, an inference.

The Monday, August 3, 2026 release gave second-quarter net revenue of USD 13.5 million, flat year on year, a net loss of USD 78.8 million and cash of USD 598.6 million, which runs into 2028. A positive pre-NDA meeting with the Food and Drug Administration (FDA) was announced on Tuesday, September 15, 2026, and a new drug application for Axpaxli in wet age-related macular degeneration is planned for the fourth quarter of 2026. The valuation rests on one candidate, and regulatory delay and equity issuance are the named risks.

Alaunos Therapeutics (NASDAQ:TCRT): a recapitalisation around new programmes

Alaunos Therapeutics (NASDAQ:TCRT) has shifted from T-cell receptor oncology toward obesity and cardiopulmonary work. Its pre-market price was USD 2.19, and nothing dated Wednesday, October 28, 2026 or earlier accompanied the rise. The key recent event is the acquisition of Velaris Therapeutics, a private developer of pulmonary arterial hypertension therapies, completed Tuesday, October 13, 2026 alongside about USD 350 million of financing. The move seems tied to trading around that deal and thin liquidity, an inference.

Management expects the proceeds to fund operations into 2029, versus cash of about USD 0.354 million at March 31, 2026. Converting the Series C preferred needs stockholder approval and would produce roughly 358.59 million common shares on an as-converted basis, so dilution is significant. The quote is around 52.5% above the USD 1.4357 common price in the financing, a figure derived from division. A reverse split with a ratio still to be set is planned.

Where Things Stand

In short, the five gains reflect thin pre-market trading and clinical-stage or early commercial status more than a shared catalyst. Aptevo Therapeutics (NASDAQ:APVO) has the freshest data, Alaunos Therapeutics (NASDAQ:TCRT) the biggest balance sheet change and Ocular Therapeutix (NASDAQ:OCUL) the clearest regulatory path. Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) and Dyadic International (NASDAQ:DYAI) rose without a dated announcement and carry listing or going-concern concerns. Coming up: the Federal Reserve decision later on Wednesday, October 28, 2026, the SITC Annual Meeting from Wednesday, November 4, 2026 and the Axpaxli filing targeted for the fourth quarter of 2026. Pre-market prices are snapshots that can change, and this is not investment advice.